Hypertension Clinical Trial
Official title:
Effects of Different Types of Exercise on Cognitive Function in Postmenopausal Hypertensive Women
Brief Summary: The study was conducted in two parts, the first of which was carried out using a cross-sectional design approach to explore the relationship between cognitive function and autonomic function, brain function, inflammation and oxidative stress, vascular function, fitness levels, cardiorespiratory endurance and lipid metabolism. The second part uses a repeated measures design approach in a randomised controlled design to explore the effects of different types of exercise on cognitive decline in postmenopausal hypertensive women and their mechanisms of action.
Status | Recruiting |
Enrollment | 183 |
Est. completion date | December 31, 2024 |
Est. primary completion date | April 23, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 55 Years to 65 Years |
Eligibility | 1. postmenopausal HTN women aged 55 to 65 years 2. 140 mm Hg = SBP < 160 mm Hg) and/or 90 mmHg < DBP < 99 mmHg (2016 edition of the Chinese guidelines for hypertension control) 3. non-persistent hypertension (i.e., continuous use of three or more antihypertensive drugs and blood pressure still within the normal range, or continuous use of four or more antihypertensive drugs to control blood pressure 4. no other metabolic and cardiovascular problems 5. able to participate in physical activity 6. no exercise habit (no more than 6,000 steps per day) 7. alcohol and smoking prohibited 8. moderate risk classification of having cardiovascular disease 9. voluntary participation Exclusion criteria: 1 pre-menopausal, not falling under the above conditions 2 blood pressure not exceeding the above range 3 refractory hypertension and secondary hypertension 4 metabolic and cardiovascular diseases 5 unable to exercise for their own reasons 6 regular exercise (more than 6,000 steps per day) 7 poor lifestyle habits such as alcohol and smoking 8 suffering from cardiovascular disease risk classification of high or low b. Inclusion criteria for the negative control group: 1. postmenopausal women aged 55 to 65 years 2. SBP = 120 mmHg, DBP < 90 mmHg 3. good physical condition 4. practice daily exercise (more than 6000 times daily) 5. do not drink or smoke 6. have a risk classification of no risk for cardiovascular disease 7. voluntary participation Exclusion criteria: 1. pre-menopausal and not in the above category 2. SBP and DBP values below normal 3. general health, disability or other medical conditions 4. poor diet, alcohol abuse, smoking, etc. 5. no low risk cardiovascular risk classification |
Country | Name | City | State |
---|---|---|---|
China | School of Sports Medicine and Rehabilitation, Beijing Sport University | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Sport University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MOCA score | The change of MOCA score. Montreal cognitive assessment (MoCA). The MoCA scale includes cognitive functions such as visuospatial and executive functions, naming, attention, language, abstraction, delayed recall and orientation, and evaluates the level of cognitive function from several cognitive dimensions. The MoCA has a total score of 30 questions, with 26 being normal and <26 being cognitive decline. | 12 weeks | |
Secondary | Blood pressure | The change of blood pressure before and after intervention. | 12 weeks | |
Secondary | Quiet heart rate | The change of quiet heart rate before and after intervention. | 12 weeks | |
Secondary | Waist and hip circumference | The change of waist circumference and hip circumference before and after intervention. | 12 weeks | |
Secondary | Body fat percentage | The change of body fat percentage before and after intervention. | 12 weeks | |
Secondary | Lipid metabolism indicators | The change of lipid metabolism indicators before and after intervention. Lipid metabolism indicators include: total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). | 12 weeks | |
Secondary | Cardiorespiratory endurance indicator | The change of cardiopulmonary endurance indicator before and after intervention. Cardiopulmonary endurance indicator: maximal oxygen uptake (VO2max) was determined using exercise cardiorespiratory testing system. | 12 weeks | |
Secondary | Serum interleukin-6 (IL-6) | The change of inflammation indicators before and after intervention. | 12 weeks | |
Secondary | High-sensitivity C-reactive protein (hs-CRP) | The change of inflammation indicators before and after intervention. | 12 weeks | |
Secondary | Vascular endothelial growth factor (VEGF) | The change of growth factor indicators before and after intervention. | 12 weeks | |
Secondary | Insulin-like growth factor(IGF-1) | The change of growth factor indicators before and after intervention. | 12 weeks | |
Secondary | Malondialdehyde (MDA) | The change of malondialdehyde (MDA) level before and after intervention. | 12 weeks | |
Secondary | Superoxide dismutase (SOD) | The change of superoxide dismutase (SOD) level before and after intervention. | 12 weeks | |
Secondary | Nitric oxide (NO) | The change of nitric oxide (NO) level before and after intervention. | 12 weeks | |
Secondary | Heart rate variability (HRV) | The change of heart rate variability (HRV) before and after intervention. | 12 weeks | |
Secondary | Mean flow rate (Vm) of middle cerebral artery and carotid artery | The change of middle cerebral artery mean flow rate and carotid artery mean flow rate before and after intervention. | 12 weeks | |
Secondary | Resistance index (RI) of middle cerebral artery and carotid artery | The change of middle cerebral artery resistance index and carotid artery resistance index before and after intervention. | 12 weeks | |
Secondary | Pulsatility index (PI) of middle cerebral artery and carotid artery | The change of middle cerebral artery pulsatility index and carotid artery pulsatility index before and after intervention. | 12 weeks | |
Secondary | Peak systolic velocity (PSV) and end-diastolic velocity (EDV) of carotid artery | The change of peak systolic velocity and end-diastolic velocity of carotid artery before and after intervention. | 12 weeks | |
Secondary | Vascular endothelial function indicator: Flow-mediated dilation (FMD) | The change of flow-mediated dilation before and after intervention. | 12 weeks | |
Secondary | Artery stiffness indicator: Carotid-femoral pulse artery stiffness (cfPWV). | The change of carotid-femoral pulse artery stiffness (cfPWV) before and after intervention. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |